Sandoz Group (OTCMKTS:SDZNY) Sees Unusually-High Trading Volume – Here’s Why

Sandoz Group AG Sponsored ADR (OTCMKTS:SDZNY) saw an uptick in trading volume on Friday . 46,457 shares were traded during trading, an increase of 181% from the previous session’s volume of 16,560 shares.The stock last traded at $77.17 and had previously closed at $75.66.

Wall Street Analysts Forecast Growth

Separately, Barclays upgraded shares of Sandoz Group to a “strong-buy” rating in a research note on Monday, October 13th. One analyst has rated the stock with a Strong Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, Sandoz Group presently has an average rating of “Moderate Buy”.

Sandoz Group Stock Performance

The company has a quick ratio of 0.82, a current ratio of 1.29 and a debt-to-equity ratio of 0.62. The firm has a 50 day simple moving average of $71.84 and a 200-day simple moving average of $64.03.

Sandoz Group Company Profile

Sandoz Group (OTCMKTS:SDZNY) is a multinational pharmaceutical company focused on the development, manufacturing and commercialization of generic medicines and biosimilars. The company supplies off-patent small-molecule drugs as well as biologic alternatives intended to offer lower-cost therapeutic options across a range of clinical areas. Sandoz emphasizes access and affordability, positioning its portfolio to serve hospitals, pharmacies and health systems looking to expand patient access to essential therapies.

The company’s product offerings span conventional generics, complex and specialty generics, and a growing pipeline of biosimilar medicines.